S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
NASDAQ:IPSC

Century Therapeutics (IPSC) Stock Price, News & Analysis

$4.30
+0.03 (+0.70%)
(As of 12:28 PM ET)
Today's Range
$4.05
$4.39
50-Day Range
$3.47
$5.32
52-Week Range
$1.28
$5.51
Volume
18,444 shs
Average Volume
219,822 shs
Market Capitalization
$278.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.17

Century Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
234.1% Upside
$14.17 Price Target
Short Interest
Healthy
7.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Century Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$127,635 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.02) to ($2.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

Medical Sector

714th out of 939 stocks

Biotechnology Industry

13th out of 24 stocks

IPSC stock logo

About Century Therapeutics Stock (NASDAQ:IPSC)

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

IPSC Stock Price History

IPSC Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Century Therapeutics: Q4 Earnings Insights
IPSC Century Therapeutics, Inc.
Century Therapeutics Inc (IPSC)
See More Headlines
Receive IPSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Century Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IPSC
Fax
N/A
Employees
163
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.17
High Stock Price Target
$24.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+231.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-136,670,000.00
Net Margins
-6,115.12%
Pretax Margin
-6,030.96%

Debt

Sales & Book Value

Annual Sales
$2.23 million
Book Value
$3.09 per share

Miscellaneous

Free Float
59,892,000
Market Cap
$276.78 million
Optionable
Optionable
Beta
1.29
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Adrienne Farid Ph.D. (Age 62)
    COO & Head of Early Development
    Comp: $650.66k
  • Mr. Brent Pfeiffenberger M.B.A.
    Pharm.D., CEO & Director
  • Mr. Douglas Carr CPA
    Interim Principal Financial Officer, Senior VP of Finance & Operations and Secretary
  • Dr. Gregory Russotti Ph.D. (Age 57)
    Chief Technology & Manufacturing Officer
  • Mr. Kenneth J. Dow J.D.
    Senior VP of General Counsel
  • Dr. Shane Williams Ph.D.
    Chief People Officer
  • Dr. Hyam I. Levitsky M.D. (Age 66)
    President of Research & Development
    Comp: $502.12k
  • Michael Naso Ph.D.
    Senior VP of Cell Engineering
  • Dr. Nick Trede M.D.
    Ph.D., Senior VP & Head of Clinical Development

IPSC Stock Analysis - Frequently Asked Questions

Should I buy or sell Century Therapeutics stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Century Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IPSC shares.
View IPSC analyst ratings
or view top-rated stocks.

What is Century Therapeutics' stock price target for 2024?

6 equities research analysts have issued 1 year price targets for Century Therapeutics' stock. Their IPSC share price targets range from $5.00 to $24.00. On average, they predict the company's share price to reach $14.17 in the next twelve months. This suggests a possible upside of 234.1% from the stock's current price.
View analysts price targets for IPSC
or view top-rated stocks among Wall Street analysts.

How have IPSC shares performed in 2024?

Century Therapeutics' stock was trading at $3.32 at the start of the year. Since then, IPSC shares have increased by 27.7% and is now trading at $4.24.
View the best growth stocks for 2024 here
.

Are investors shorting Century Therapeutics?

Century Therapeutics saw a decrease in short interest in March. As of March 15th, there was short interest totaling 1,640,000 shares, a decrease of 6.3% from the February 29th total of 1,750,000 shares. Based on an average daily volume of 214,300 shares, the short-interest ratio is presently 7.7 days. Approximately 7.6% of the company's shares are short sold.
View Century Therapeutics' Short Interest
.

When is Century Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IPSC earnings forecast
.

How were Century Therapeutics' earnings last quarter?

Century Therapeutics, Inc. (NASDAQ:IPSC) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. The business had revenue of $0.27 million for the quarter, compared to analysts' expectations of $1.69 million. Century Therapeutics had a negative net margin of 6,115.12% and a negative trailing twelve-month return on equity of 54.73%.

When did Century Therapeutics IPO?

Century Therapeutics (IPSC) raised $201 million in an initial public offering (IPO) on Friday, June 18th 2021. The company issued 10,600,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are Century Therapeutics' major shareholders?

Century Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Avidity Partners Management LP (2.26%), Vanguard Group Inc. (1.88%), Vanguard Group Inc. (1.88%), Federated Hermes Inc. (1.03%), Bridgeway Capital Management LLC (0.20%) and New York Life Investment Management LLC (0.17%). Insiders that own company stock include Adrienne Farid, Douglas Carr, Eli Casdin, Luis Borges and Versant Venture Capital Vi, L.
View institutional ownership trends
.

How do I buy shares of Century Therapeutics?

Shares of IPSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IPSC) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners